FluMist Nasal Spray Vaccine Now Available for Home Delivery
AstraZeneca now offers FluMist Home, allowing eligible patients to receive and self-administer the flu vaccine entirely at home.
AstraZeneca will now provide a home delivery option for its nasal spray flu vaccine FluMist, according to a release from the company.1 With FluMist Home, patients who are prescribed the vaccine can place an order through the independent online specialty pharmacy ASPN Pharmacies and have it delivered to their home via Polaris Pharmacy Services.
FluMist Nasal Spray Vaccine Now Available for Home Delivery / DragonImages - stock.adobe.com
“As influenza vaccination rates decline, especially among younger populations, this first-of-its-kind, at-home, needle-free option offers a critical opportunity to help make protection more accessible, convenient, and better aligned with the realities and current preferences of people’s lives,” Ravi Jhaveri, MD, professor of pediatrics at Northwestern University School of Medicine, said in a release.1
FluMist is the first and only seasonal flu vaccine approved to be self-administered by adults 18 to 49 years of age or by a caregiver to individuals 2 to 17 years of age. The live attenuated vaccine was first approved by the FDA in 2003 and received approval for self-administration in 2024. The self-administration approval was based on data that showed the vaccine instructions were appropriately designed so recipients and caregivers could safely and effectively use it.2 FluMist is approved for the prevention of flu caused by influenza virus subtypes A and B.
FluMist Home is delivered in a consumer-friendly format with clear, at-home specific instructions that support proper handling, administration, and disposal. The vaccine should be stored in the refrigerator until it is ready to be used. The most common side effects of FluMist include runny or stuffy nose, sore throat, and fever over 100 degrees. It should be avoided if a patient is allergic to eggs or other flu vaccines.
“Seasonal influenza can have a serious, even life-altering, impact on individuals and families, especially for those most vulnerable,” Michele Slafkosky, executive director of Families Fight Flu, said in a release.1 “Providing flexible vaccination options makes it easier for individuals and caregivers to help get protected. This can help to improve protection for individuals and strengthen collective immunity against influenza.”
AstraZeneca said in the release that FluMist Home will be available in 34 states and the company aims to eventually have it available in all 48 contiguous states. Although the service is not allowed in certain states due to local pharmacy laws, it remains available in both doctors’ offices and pharmacies for administration across the country.
“For the first time, consumers can receive and administer an influenza vaccine entirely at home—marking a historic shift in how preventive care is delivered,” Ami Patel, executive vice president of hub operations at ASPN Pharmacies, said in a release.1 “Through FluMist Home we’re seeing a new model of care that puts consumers in control, offering a seamless, end-to-end experience, from determining eligibility to convenient home-delivery and administration. This milestone not only redefines convenience in vaccine delivery, but also sets the stage for a more accessible, patient-centered future in healthcare.”
READ MORE: Immunization Resource Center
Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.
References
1. FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery. News Release. AstraZeneca. August 15, 2025. Accessed August 15, 2025. https://www.astrazeneca-us.com/media/press-releases/2025/FLUMIST-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery.html
2. FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration. News Release. FDA. September 20, 2024 Accessed August 15, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-spray-influenza-vaccine-self-or-caregiver-administration
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
